Literature DB >> 20493839

Application of isoproterenol inhibits diabetic-like changes in the rat retina.

Youde Jiang1, Robert J Walker, Timothy S Kern, Jena J Steinle.   

Abstract

Diabetic retinopathy is the leading cause of blindness to working-age adults. We have recently shown that surgical removal or genetic manipulations to eliminate sympathetic neurotransmission produces many of the retinal changes similar to rodent diabetic retinopathy with normal glucose levels. We hypothesized that application of a beta-adrenergic receptor agonist, isoproterenol, could reach the retina to elicit normal cellular signaling and inhibit the functional and morphological markers of early stage diabetic retinopathy in the rat. Rats were made diabetic by injection of 60 mg/kg streptozotocin. Within 3 days of diabetes-induction, rats were placed into 1 of 3 groups (control, diabetes, or diabetic + isoproterenol). Dose and time course studies were done for isoproterenol using a PKA ELISA and CREB analyses. Once the optimal dose and time course were established, electrical activity of the retina was analyzed by electroretinogram each month for the 8-month study. Western blotting was done for insulin receptor signaling and Akt and ELISA analyses for TNFalpha concentration and cleavage of caspase 3 at 2- and 8-months of diabetes. Diabetes-induced degeneration of neural cells and retinal thickness were assessed at 2 months, while degenerate capillaries were quantitated at 8 months of treatment. Daily application of 50 mM isoproterenol was effective in inhibiting the diabetes-induced loss of a- and b-wave and oscillatory potential amplitudes in the electroretinogram. Isoproterenol blocked the increase in TNFalpha and apoptosis in the diabetic retina. The numbers of degenerate capillaries were also reduced in the treated + diabetes retina. These data strongly suggest that loss of beta-adrenergic receptor signaling may be a key factors in early stage diabetic retinopathy. Resolution of this loss of adrenergic receptor signaling can inhibit some of the hallmarks of diabetic retinopathy in the retina. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20493839      PMCID: PMC4319116          DOI: 10.1016/j.exer.2010.04.014

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  32 in total

1.  Diabetic retinopathy.

Authors:  J R WOLTER
Journal:  Am J Ophthalmol       Date:  1961-05       Impact factor: 5.258

2.  Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.

Authors:  Timothy S Kern; Casey M Miller; Yunpeng Du; Ling Zheng; Susanne Mohr; Sherry L Ball; M Kim; Jeffrey A Jamison; David P Bingaman
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

3.  Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy.

Authors:  R A Kowluru; J Tang; T S Kern
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

4.  Sympathetic neurotransmission modulates expression of inflammatory markers in the rat retina.

Authors:  Jena J Steinle
Journal:  Exp Eye Res       Date:  2006-10-24       Impact factor: 3.467

5.  Increased basement membrane thickness, pericyte ghosts, and loss of retinal thickness and cells in dopamine beta hydroxylase knockout mice.

Authors:  Jena J Steinle; Timothy S Kern; Steven A Thomas; Lisa S McFadyen-Ketchum; Christopher P Smith
Journal:  Exp Eye Res       Date:  2009-01-07       Impact factor: 3.467

6.  Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.

Authors:  A J Barber; E Lieth; S A Khin; D A Antonetti; A G Buchanan; T W Gardner
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

7.  The 15-amino acid motif of the C terminus of the beta2-adrenergic receptor is sufficient to confer insulin-stimulated counterregulation to the beta1-adrenergic receptor.

Authors:  Shai Gavi; Dezhong Yin; Elena Shumay; Hsien-Yu Wang; Craig C Malbon
Journal:  Endocrinology       Date:  2004-09-23       Impact factor: 4.736

8.  A central role for inflammation in the pathogenesis of diabetic retinopathy.

Authors:  Antonia M Joussen; Vassiliki Poulaki; Minh Ly Le; Kan Koizumi; Christina Esser; Hanna Janicki; Ulrich Schraermeyer; Norbert Kociok; Sascha Fauser; Bernd Kirchhof; Timothy S Kern; Anthony P Adamis
Journal:  FASEB J       Date:  2004-07-01       Impact factor: 5.191

9.  Systemic propranolol reduces b-wave amplitude in the ERG and increases IGF-1 receptor phosphorylation in rat retina.

Authors:  Youde Jiang; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-30       Impact factor: 4.799

10.  Wavelet analysis reveals dynamics of rat oscillatory potentials.

Authors:  Jason D Forte; Bang V Bui; Algis J Vingrys
Journal:  J Neurosci Methods       Date:  2007-12-23       Impact factor: 2.390

View more
  24 in total

1.  Adrenergic and serotonin receptors affect retinal superoxide generation in diabetic mice: relationship to capillary degeneration and permeability.

Authors:  Yunpeng Du; Megan Cramer; Chieh Allen Lee; Jie Tang; Arivalagan Muthusamy; David A Antonetti; Hui Jin; Krzysztof Palczewski; Timothy S Kern
Journal:  FASEB J       Date:  2015-02-09       Impact factor: 5.191

2.  TNFα and SOCS3 regulate IRS-1 to increase retinal endothelial cell apoptosis.

Authors:  Youde Jiang; Qiuhua Zhang; Carl Soderland; Jena J Steinle
Journal:  Cell Signal       Date:  2012-01-12       Impact factor: 4.315

3.  Role of β-adrenergic receptor regulation of TNF-α and insulin signaling in retinal Muller cells.

Authors:  Robert J Walker; Nancy M Anderson; Youde Jiang; Suleiman Bahouth; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-12-16       Impact factor: 4.799

Review 4.  Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy.

Authors:  Sayon Roy; Timothy S Kern; Brian Song; Caren Stuebe
Journal:  Am J Pathol       Date:  2016-11-12       Impact factor: 4.307

5.  Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels.

Authors:  Qiuhua Zhang; Kimberly Guy; Jayaprakash Pagadala; Youde Jiang; Robert J Walker; Luhong Liu; Carl Soderland; Timothy S Kern; Robert Ferry; Hui He; C Ryan Yates; Duane D Miller; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-17       Impact factor: 4.799

6.  Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy.

Authors:  Jing Chen; Jean-Sebastian Joyal; Colman J Hatton; Aimee M Juan; Dorothy T Pei; Christian G Hurst; Dan Xu; Andreas Stahl; Ann Hellstrom; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-17       Impact factor: 4.799

7.  A sensitive and fast LC-MS/MS method for determination of β-receptor agonist JP-49b: application to a pharmacokinetic study in rats.

Authors:  Hui He; Kimberly Williams-Guy; Jayaprakash Pagadala; Chaela Sickbert Presley; Duane D Miller; Jena J Steinle; Charles R Yates
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-02-08       Impact factor: 3.205

8.  IGFBP-3 and TNF-α regulate retinal endothelial cell apoptosis.

Authors:  Qiuhua Zhang; Youde Jiang; Matthew J Miller; Bonnie Peng; Li Liu; Carl Soderland; Jie Tang; Timothy S Kern; John Pintar; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-09       Impact factor: 4.799

9.  Increased tumor necrosis factor-α, cleaved caspase 3 levels and insulin receptor substrate-1 phosphorylation in the β₁-adrenergic receptor knockout mouse.

Authors:  Surekha Rani Panjala; Youde Jiang; Timothy S Kern; Steven A Thomas; Jena J Steinle
Journal:  Mol Vis       Date:  2011-07-06       Impact factor: 2.367

10.  Reduced insulin receptor signaling in retinal Müller cells cultured in high glucose.

Authors:  Youde Jiang; Jayaprakash Pagadala; Duane Miller; Jena J Steinle
Journal:  Mol Vis       Date:  2013-04-05       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.